Genmab | GEN - Cash And Equivalent


Genmab reported DKK1.5B in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Agios Pharmaceuticals USD 99.65M 13.95M Jun/2026
Almirall EUR 337.77M 14.83M Dec/2025
Amarin USD 143.56M 12.5M Jun/2026
Amgen USD 13.99B 1.95B Jun/2026
argenx SE USD 4.3B 808.71M Mar/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Bayer EUR 4.29B 1.44B Jun/2026
BioMarin Pharmaceutical USD 874M 1.35B Jun/2026
Demant DKK 1.33B 188M Dec/2025
Exelixis USD 281.45M 55.3M Jun/2026
Fresenius Medical Care EUR 1.06B 177.89M Jun/2026
Genmab DKK 1.5B 18M Jun/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
GN Store Nord DKK 865M 254M Mar/2026
GRIFOLS EUR 513M 189M Jun/2026
Hikma Pharmaceutical USD 217M 19M Dec/2025
Insmed USD 544.76M 37.42M Jun/2026
Lakefront Biotherapeutics EUR 135.95M 69.15M Jun/2026
Lonza CHF 719M 188M Dec/2025
Merck EUR 2.74B 415M Mar/2026
Novartis USD 7.62B 739M Jun/2026
Regeneron Pharmaceuticals USD 2.46B 506.8M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
UCB EUR 1.57B 1.14B Dec/2024